• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

莫索尼定和比索洛尔对绝经后妇女动脉高血压和骨质疏松症的动脉壁形态功能状况和端粒酶活性的影响。莫斯科随机研究的结果。

Influence of Moxonidine and Bisoprolol on Morphofunctional Condition of Arterial Wall and Telomerase Activity in Postmenopausal Women with Arterial Hypertension and Osteopenia. The Results from a Moscow Randomized Study.

机构信息

Laboratory of Age-related Metabolic Endocrine Disorders of Pirogov Russian National Research Medical University of Ministry of Health of Russian Federation "Russian Gerontology Research and Clinical Centre", Moscow, Russia.

National Medical Research Centre for Therapy and Preventive Medicine, Moscow, Russia.

出版信息

Cardiovasc Drugs Ther. 2022 Dec;36(6):1147-1155. doi: 10.1007/s10557-021-07235-6. Epub 2021 Sep 15.

DOI:10.1007/s10557-021-07235-6
PMID:34524565
Abstract

PURPOSE

To compare the effect of 12 months of treatment with moxonidine or bisoprolol on telomerase activity (TA) and parameters characterizing the arterial wall state in postmenopausal women with arterial hypertension (AH) and osteopenia.

METHODS

An open-label randomized study with 114 postmenopausal women with hypertension and osteopenia; pulse wave velocity (PWV), intima-media thickness (IMT), and TA were analyzed initially and after 12 months of therapy with moxonidine (n = 57) or bisoprolol (n = 57).

RESULTS

Both medications effectively lowered blood pressure (BP) in both groups. After 12 months, the moxonidine group showed a significant increase in TA by 45.5% (from 0.87 to 1.15; p < 0.001), in contrast to the bisoprolol group, where TA decreased by 14.1% (from 0.89 to 0.74; p = 0.001). Within 12 months, in the moxonidine group, PWV decreased by 1.9% (from 10.35 ± 2.56 to 10.05 ± 2.29 m/s; p = 0.039), and in the bisoprolol group it increased by 5.8% (from 10.36 ± 2.47 to 11.26 ± 2.60 m/s; p < 0.001). In the moxonidine group, IMT increased by 3.5% on the right and 1.4% on the left, in the bisoprolol group - by 5.7% on the right and 4.2% on the left.

CONCLUSION

A 12-month treatment with moxonidine but not with bisoprolol in postmenopausal women with AH and osteoporosis was associated with a decrease of arterial stiffness seen as statistically significantly reduced PVW and with increased TA.

摘要

目的

比较莫索尼定和比索洛尔治疗 12 个月对绝经后女性动脉高血压(AH)和骨质疏松症患者端粒酶活性(TA)和动脉壁状态参数的影响。

方法

这是一项开放标签、随机研究,纳入了 114 名绝经后高血压合并骨质疏松症患者;最初和治疗 12 个月后,分析脉搏波速度(PWV)、内膜中层厚度(IMT)和 TA,这些患者分别接受莫索尼定(n = 57)或比索洛尔(n = 57)治疗。

结果

两种药物均能有效降低两组患者的血压(BP)。12 个月后,莫索尼定组 TA 显著升高 45.5%(从 0.87 升至 1.15;p < 0.001),而比索洛尔组 TA 降低 14.1%(从 0.89 降至 0.74;p = 0.001)。在 12 个月内,莫索尼定组 PWV 降低 1.9%(从 10.35 ± 2.56 降至 10.05 ± 2.29 m/s;p = 0.039),而比索洛尔组增加 5.8%(从 10.36 ± 2.47 增至 11.26 ± 2.60 m/s;p < 0.001)。莫索尼定组右侧 IMT 增加 3.5%,左侧增加 1.4%,比索洛尔组右侧增加 5.7%,左侧增加 4.2%。

结论

在绝经后 AH 和骨质疏松症女性中,12 个月的莫索尼定治疗而不是比索洛尔治疗与动脉僵硬度降低有关,表现为 PWV 统计学显著降低,TA 增加。

相似文献

1
Influence of Moxonidine and Bisoprolol on Morphofunctional Condition of Arterial Wall and Telomerase Activity in Postmenopausal Women with Arterial Hypertension and Osteopenia. The Results from a Moscow Randomized Study.莫索尼定和比索洛尔对绝经后妇女动脉高血压和骨质疏松症的动脉壁形态功能状况和端粒酶活性的影响。莫斯科随机研究的结果。
Cardiovasc Drugs Ther. 2022 Dec;36(6):1147-1155. doi: 10.1007/s10557-021-07235-6. Epub 2021 Sep 15.
2
[New possibilities of using moxonidin for blood pressure control in female patients with osteopenia].[莫索尼定用于控制女性骨质疏松症患者血压的新可能性]
Kardiologiia. 2018;58(S7):36-45.
3
Comparative effectiveness of a fixed-dose combination of losartan + HCTZ versus bisoprolol + HCTZ in patients with moderate-to-severe hypertension: results of the 6-month ELIZA trial.氯沙坦+氢氯噻嗪固定剂量复方制剂与比索洛尔+氢氯噻嗪治疗中重度高血压患者的疗效比较:6个月ELIZA试验结果
Vasc Health Risk Manag. 2013;9:535-49. doi: 10.2147/VHRM.S44568. Epub 2013 Sep 27.
4
[The Fixed Combination of Amlodipine and Bisoprolol Eliminates the Effect of -Blockers on Central Pulse Wave in Patients With Arterial Hypertension].[氨氯地平和比索洛尔固定复方消除了β受体阻滞剂对高血压患者中心动脉脉搏波的影响]
Kardiologiia. 2015 Dec;55(12):11-16. doi: 10.18565/cardio.2015.12.11-16.
5
Physical activity is associated with lower arterial stiffness in normal-weight postmenopausal women.身体活动与正常体重绝经后女性较低的动脉僵硬度有关。
J Clin Hypertens (Greenwich). 2020 Sep;22(9):1682-1690. doi: 10.1111/jch.13954. Epub 2020 Aug 20.
6
[Comparison of the effectiveness of moxonidine and prestarium in postmenopausal women with mild and moderate arterial hypertension].[莫索尼定与普司他明对绝经后轻中度动脉高血压女性疗效的比较]
Klin Med (Mosk). 2006;84(4):41-4.
7
Effects of Celiprolol and Bisoprolol on Blood Pressure, Vascular Stiffness, and Baroreflex Sensitivity.塞利洛尔和比索洛尔对血压、血管硬度及压力感受器反射敏感性的影响
Am J Hypertens. 2015 Jul;28(7):858-67. doi: 10.1093/ajh/hpu245. Epub 2015 Jan 10.
8
Comparison of atenolol versus bisoprolol with noninvasive hemodynamic and pulse wave assessment.阿替洛尔与比索洛尔的比较:无创血流动力学和脉搏波评估
J Am Soc Hypertens. 2015 May;9(5):390-6. doi: 10.1016/j.jash.2015.02.013. Epub 2015 Feb 23.
9
Whole-body vibration exercise training reduces arterial stiffness in postmenopausal women with prehypertension and hypertension.全身振动运动训练可降低绝经后高血压前期和高血压女性的动脉僵硬度。
Menopause. 2014 Feb;21(2):131-6. doi: 10.1097/GME.0b013e318294528c.
10
Arterial stiffness, carotid atherosclerosis and left ventricular diastolic dysfunction in postmenopausal women.绝经后妇女的动脉僵硬度、颈动脉粥样硬化和左心室舒张功能障碍。
Eur J Intern Med. 2013 Apr;24(3):250-4. doi: 10.1016/j.ejim.2012.11.019. Epub 2012 Dec 28.

引用本文的文献

1
Hypertension and cellular senescence.高血压与细胞衰老。
Biogerontology. 2023 Aug;24(4):457-478. doi: 10.1007/s10522-023-10031-4. Epub 2023 Apr 3.

本文引用的文献

1
Telomere length and telomerase activity in osteoporosis and osteoarthritis.骨质疏松症和骨关节炎中的端粒长度及端粒酶活性
Exp Ther Med. 2020 Mar;19(3):1626-1632. doi: 10.3892/etm.2019.8370. Epub 2019 Dec 24.
2
2018 ESC/ESH Guidelines for the management of arterial hypertension.2018年欧洲心脏病学会/欧洲高血压学会动脉高血压管理指南。
Eur Heart J. 2018 Sep 1;39(33):3021-3104. doi: 10.1093/eurheartj/ehy339.
3
Telomeres and telomerase in heart regeneration.心脏再生中的端粒与端粒酶
Differentiation. 2018 Mar-Apr;100:26-30. doi: 10.1016/j.diff.2018.01.003. Epub 2018 Feb 3.
4
Low bone mineral density is associated with increased risk for myocardial infarction in men and women.低骨密度与男性和女性心肌梗死风险增加有关。
Osteoporos Int. 2012 Mar;23(3):963-70. doi: 10.1007/s00198-011-1631-0. Epub 2011 Apr 20.
5
Vascular aging: A tale of EVA and ADAM in cardiovascular risk assessment and prevention.血管衰老:心血管风险评估与预防中EVA和ADAM的故事
Hypertension. 2009 Jul;54(1):3-10. doi: 10.1161/HYPERTENSIONAHA.109.129114. Epub 2009 Jun 1.
6
Telomeres and telomerase: the path from maize, Tetrahymena and yeast to human cancer and aging.端粒与端粒酶:从玉米、四膜虫和酵母到人类癌症与衰老的历程
Nat Med. 2006 Oct;12(10):1133-8. doi: 10.1038/nm1006-1133.
7
Randomization and allocation concealment: a practical guide for researchers.随机化与分配隐藏:研究人员实用指南
J Crit Care. 2005 Jun;20(2):187-91; discussion 191-3. doi: 10.1016/j.jcrc.2005.04.005.
8
Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study.莫索尼定治疗超重和肥胖代谢综合征患者:一项上市后监测研究
J Hum Hypertens. 2004 Sep;18(9):669-75. doi: 10.1038/sj.jhh.1001676.
9
Osteoporosis and cardiovascular disease: brittle bones and boned arteries, is there a link?骨质疏松症与心血管疾病:脆弱骨骼与“骨化”动脉,二者有关联吗?
Endocrine. 2004 Feb;23(1):1-10. doi: 10.1385/ENDO:23:1:01.
10
Telomere states and cell fates.端粒状态与细胞命运。
Nature. 2000 Nov 2;408(6808):53-6. doi: 10.1038/35040500.